KRYS News and Press, Krystal Biotech Inc. From 08/25/20

Krystal Biotech ( KRYS +0.2% ) has initiated PEARL 1 (Phase 1) study of KB301 for acne scars and facial wrinkles. More news on: Krystal Biotech, Inc., Healthcare stocks news, Read more ...

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection  First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH, Aug. 25, 20...

PITTSBURGH, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the U.S. Food & Drug Administration (FDA) has gran...

Krystal Biotech (NASDAQ: KRYS ) : Q2 GAAP EPS of -$0.37 beats by $0.06 . More news on: Krystal Biotech, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairm...

Krystal Biotech ( KRYS -3.2% )  initiates  pivotal Phase 3 (GEM-3) trial evaluating topical gene therapy bercolagene telserpavec (B-VEC, previously KB103) for treatment of dystrophic epidermolysis bullosa (DEB) patients. More news on: Krystal Biotech, Inc., Healthcare...

The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB) patients  Top line data and BLA filing are anticipated in 2021; EMA aligned on pivotal study design and an MAA is anticipated...

PITTSBURGH, July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created posi...

Quick Take Krystal Biotech (KRYS) has been developing game-changing, innovative topical gene therapies for serious diseases. Krystal went public in 2017 at around $10 a share and, currently, trades in the mid-forties and has a market cap close to $850 million. A legal ruling against Krysta...